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Background: Pneumocystis pneumonia (PCP) is an important cause of hospitalization and mortality in HIV-infected
children. However, the incidence of PCP has been underestimated due to poor sensitivity of diagnostic tests. The
use of polymerase chain reaction (PCR) for pneumocystis has enabled more reliable diagnosis. This study describes
the incidence, clinical features and outcome of PCP in South African children diagnosed using PCR.
Methods: A prospective study of children hospitalised in South Africa with suspected PCP was done from November
2006 to August 2008. Clinical, laboratory and radiological information were collected. Lower respiratory tract specimens
were obtained for PCP immunofluorescence (IF), real- time PCR for pneumocystis, bacterial and mycobacterial culture.
Nasopharyngeal aspirates were taken for immunofluorescence (IF), real-time PCR for pneumocystis and PCR for
respiratory viruses. A blood specimen for bacterial culture and for cytomegalovirus PCR was taken. Children were
followed for the duration of their hospitalisation and the outcome was recorded.
Results: 202 children [median (interquartile range, IQR) age 3.2 (2.1– 4.6) months] were enrolled; 124 (61.4%) were
HIV infected. PCP was identified in 109 (54%) children using PCR, compared to 43 (21%) using IF and Grocott staining
(p < 0.0001). Most PCP cases (88, 81%) occurred in HIV-infected children. All 21 cases (19%) occurring in HIV- negative
children had another risk factor for PCP. On logistic regression, predictive factors for PCP were HIV infection, lack of
fever, high respiratory rate and low oxygen saturation whilst cotrimoxazole prophylaxis was protective (OR 0.24; 95%
CI 0.1 to 0.5; p < 0.002). The case fatality of children with PCP was higher than those without PCP (32.1% versus 17.2%;
relative risk 1.87; 95% confidence interval (CI) 1.11 – 3.15). Amongst HIV-infected children, a CD4 less than 15% was the
only independent predictor of mortality.
Conclusions: The diagnostic yield for PCP is more than 2.5 times higher on PCR than other detection methods. PCP is
a very common cause of severe hypoxic pneumonia and is associated with high mortality in HIV-infected African infants.
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Pneumocystis pneumonia (PCP) is a major cause of mor-
bidity and mortality in HIV infected infants [1-5]. Ap-
proximately 29 – 67% of respiratory related deaths among
African HIV infected children have been associated with
PCP [6-8], and in-hospital case-fatality rates range from
20 – 63% [1,2,9-11]. South African studies have reported
that the prevalence of PCP ranges from 10% to 49% among
antiretroviral naïve HIV infected children hospitalized with* Correspondence: Brenda.morrow@uct.ac.za
1Department of Paediatics and Child Health, Red Cross War Memorial
Children’s Hospital (RCWMCH), University of Cape Town, 5th Floor Institute of
Child Health Building, Klipfontein Road, Rondebosch 7700, Cape Town, South
Africa
Full list of author information is available at the end of the article
© 2014 Morrow et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpneumonia [9-11]. PCP has also been shown to occur in
HIV uninfected infants, mostly with an underlying pre-
disposing factor such as HIV exposure or malnutrition
[2,4,12-16].
The use of highly active antiretroviral therapy (HAART)
has dramatically reduced the incidence of PCP in devel-
oped countries [17-19]. However PCP remains a common
cause of hospitalization and mortality in HIV-infected
South African children [2,4]. In a recent study, 21% of chil-
dren admitted to a tertiary paediatric hospital with acute
severe hypoxic pneumonia were found to have PCP despite
a well- functioning paediatric HIV program [2]. In previous
studies, immunofluorescence (IF) or silver staining of re-
spiratory secretions have been used for the diagnosis ofl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for diagnosis, potentially leading to under recognition of
PCP [20-24].We recently reported that real-time polymer-
ase chain reaction (PCR) is more sensitive than IF for the
diagnosis of PCP when used on lower [induced sputum
(IS) or non-bronchoscopic broncho-alveolar lavage (BAL)]
or upper respiratory tract [nasopharyngeal aspirate (NPA)]
specimens. The yield for PCP from upper and lower re-
spiratory tract specimens was similar by PCR [20].
The aim of this study was to describe the incidence,
clinical features and outcome of PCP in children when
diagnosed with PCR.Methods
This was a prospective study of consecutive children
hospitalized for acute hypoxic pneumonia at Red Cross
War Memorial Children’s Hospital in Cape Town, South
Africa from November 2006 to August 2008. Inclusion
criteria were an acute onset of respiratory illness requir-
ing hospitalization, defined as age specific tachypnoea,
hypoxia and diffuse lung disease not associated with
wheezing [2]. Children were excluded if they had re-
ceived treatment for PCP in the preceding two weeks, if
they had been on PCP therapy for the acute illness for
more than 48 hours or if informed consent was not ob-
tainable. The study was approved by the Research and
Ethics Committee of the Faculty of Health Sciences at
the University of Cape Town. Written informed consent
for participation in the study was obtained from each
child’s parent or legal guardian.
Clinical, radiological and laboratory data were recorded
including symptoms, signs and oxygen saturation. The
HIV status of a child (if unknown) was confirmed using
whole-blood HIV deoxyribonucleic acid PCR (Amplicor
HIV-1 DNA test version 1.5, Roche Diagnostics, GmbH,
Mannheim, Germany) in those younger than 18 months,
or an HIV enzyme-linked immunosorbent assay (Architect
HIV Ag/Ab Combo ELISA, Abbott Laboratories, Abbott
Park, IL) in older children. CD4 counts and HIV viral
loads were done in all children newly diagnosed with HIV
and in those in whom HAART was commenced. A full
blood count and serum lactate dehydrogenase (LDH) was
done on admission.
An upper respiratory tract (NPA) and a lower respiratory
tract (LRT) specimen (IS or BAL in intubated patients)
were obtained in a standardized manner, as described pre-
viously [25,26]. Respiratory specimens were submitted for
detection of P. jirovecii by direct IF using a monoclonal
antibody (IF: Detect IF PC, Axis-Shield, UK) and Grocott
staining. Real time PCR were done on stored histopatho-
logical specimens, as described by Samuel et al. [20].
Investigation for additional pathogens included “in-
house” respiratory viral shell vial culture and rapid viralantigen detection (murine FITC-conjugated anti- RSV or
adenovirus monoclonal, Chemicon, Temecula, CA, USA)
on respiratory specimens, bacterial blood culture and bac-
terial and mycobacterial culture on IS or BAL specimens.
Blood specimens were also sent for qualitative whole blood
nested cytomegalovirus (CMV) PCR (Super-Therm, JMR
Holdings, Kent, UK). CMV pneumonia was defined as
positive CMV PCR on a blood specimen as well as detec-
tion of CMV on a LRT sample.
Children received standard therapy including oxygen,
broad spectrum antibiotics and intravenous cotrimoxa-
zole (trimethoprim-sulfamethoxazole) and oral cortico-
steroids (prednisone 1–2 mg/kg with tapered doses for
up to 21 days) as per national guidelines [27]. Eligible
children were started on HAART according to national
guidelines [28].
Statistical analysis
Continuous data were tested for normality using the
Shapiro- Wilks test. Descriptive statistics, Mann- Whitney
U tests for continuous data, and chi- square tests for
categorical data (Yates- corrected chi-square tests where
values in the cells were <10) were performed using
STATISTICA data analysis software system (version 8,
StatSoft, Inc. 2004). Forward stepwise logistic regression
analyses, to determine predictive variables for the di-
chotomous outcomes of PCP and mortality, were per-
formed using STATA (version 10.0, Statcorp, Texas,
USA). Model variables were selected if they were associ-
ated with the outcome of interest on univariate analysis
and according to biological plausibility. Variables found
to be significant when analysed jointly were included in
the final model. Weight- for- age and height- for- age Z
(or standard deviation) scores were calculated using the
Microsoft Office Excel (Microsoft Corporation 2003) add-
in ImsGrowth Program (version 2.12, Medical Research
Council UK, 2002 – 2005) (15). The WHO categorises
weight- for age and height- for age scores ≤2 as represent-
ing moderate under-nutrition and scores ≤3 representing
malnutrition [16]. A 95% significance level was chosen.
Results
Two hundred and two children [92 (45.5%) male] were
enrolled with a median (interquartile range, IQR) age
of 3.2 (2.1 – 4.6) months. HIV results were available for
200 children; 124 (61.4%) were HIV infected; 34 (16.8%)
were HIV exposed but uninfected and 42 (20.8%) were
HIV unexposed. Seventy of the HIV exposed or infected
children (44.3%) had been in the Prevention of Mother
to Child Transmission (PMTCT) program, but only 29
(18.4%) were receiving cotrimoxazole prophylaxis. Five
(4%) HIV infected children were on HAART; 72 (58%)
were started on HAART during hospitalization, at a me-
dian (IQR) of 10 (7 – 14.5) days after admission. One
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for presumed or proven CMV infection.
Most children were under- nourished with median (IQR)
weight- for age and height- for age Z scores of −2.5 (−4.3
to −1.5) and −2.3 (−3.9 to −0.9) respectively. The most
common presenting features were cough (85.1%), vomit-
ing (31.2%), diarrhoea (21.8%), or poor feeding (24.3%);
these did not differ by HIV status.
PCP
Pneumocystis jirovecii was detected in 43 (21.3%) children
by IF and/or Grocott staining and in 109 (54.0%) children
using PCR (p < 0.0001) on 107 induced sputum and 97
BAL specimens. No child was positive by IF and negative
by PCR. Eighty- seven children (79.8%) with PCP were
HIV infected (Table 1). Risk factors amongst the 21 HIV
uninfected children with PCP included malnutrition in 12
(57.1%) children, HIV exposure in 5 (23.8%); a history of
prematurity in 5 (23.8%); congenital cardiac disease in 2
(9.5%); and primary immune deficiency and post- trans-
plant immunosuppression in one child each. Clinical fea-
tures distinguishing children with PCP from those without
PCP were absence of fever, higher respiratory rate and
lower oxygen saturation on admission (Table 1).Table 1 Univariate comparison between PCP positive and neg
Variable PCP p
n =






Age (Months) 3.4 (2
HIV infected n (%) 87
HIV exposed, uninfected 5
Weight for age Z score −2.9 (−
Height for age Z score −2.4 (−
Duration of symptoms (days ) 3.0 (2
Admission signs
Respiratory rate on admission (breaths per minute) 70.0 (60
Subcostal recessions n (%) 107
SpO2 (%) in room air (n = 146) 77.0 (65
Laboratory investigations
CD4% in HIV infected children 17.1 (9
n
Lactate dehydrogenase (u/l) 710.5 (534
n
Continuous data are median (interquartile range).Co-infection
Co-infection with CMV was common in children with
PCP. The prevalence of CMV pneumonia or viraemia
was higher in children with PCP compared to those
without PCP (Table 2). In contrast other respiratory vi-
ruses were more commonly identified in children with-
out PCP (Table 2). There was no difference in the rate
of bacteraemia or culture confirmed tuberculosis be-
tween the two groups.
Predictive factors for PCP
LDH and SpO2 were not included in the multiple regres-
sion analyses due to missing data.In the final model cotri-
moxazole prophylaxis was found to be protective for PCP;
whilst HIV infection, CMV viraemia, lack of fever and
tachypnoea were associated with PCP (Table 3).
Outcome
There was no difference between children with PCP com-
pared to those without PCP in terms of PICU admission;
ventilation requirements and duration; or length of hos-
pital and PICU stay. The in-hospital mortality was 35
(32.1%) in children with PCP compared to 16 (17.2%) in
those without PCP (relative risk 1.87; 95% CI 1.11 – 3.15;ative patients by presenting clinical and laboratory data
ositive PCP negative p
109 n =93
(86.2) 78 (83.9) 0.6
(27.5) 47 (50.5) 0.0008
(25.7) 21 (22.6) 0.6
7:62 45:48 0.5
.7 – 4.0) 2.2 (1.3 – 6.8) 0.03
(79.8) 37 (39.8) <0.0001
(4.6) 29 (31.2) <0.0001
4.6 - -1.6) −2.4 (−3.9 - -1.36) 0.08
4.5 - -0.9) −2.3 (−3.2 - -0.9) 0.24
.0 – 7.0) 3.0 (1.0 – 7.0) 0.66
.0 – 80.0) 60.0 (50 – 70) 0.0002
(98.2) 83 (89.2) 0.8
.5 – 84.0) 87.5 (75.0 – 92.0) <0.0001
.9 – 29.7) 21.0 (14.7 – 29.7) 0.12
= 80 n = 35
.5 – 1067.0) 350.0 (238.0 – 610.0) <0.0001
= 57 n = 35
Table 2 Co-infection in children with and without PCP
Variable PCP positive PCP negative p
n = 109 n =93
Cytomegalovirus (CMV) blood
PCR positive
81 (74.3) 43 (46.2) <0.0001
CMV pneumonia 34 (31.2) 11 (11.8) 0.001
M. tuberculosis culture positive 1 (0.9) 4 (4.3) 0.3
Viruses other than CMV 29 (26.6) 41 (44) 0.009
Bacteraemia 7 (6.4) 13 (14.0) 0.12
Staphylococcus aureus 1 1
Escherichia coli 1 1
Klebsiella pneumoniae 1 1
Enterococcus faecalis 1 1
Streptococcus pneumoniae 0 1
Pseudomonas aeruginosa 0 3
Non-typhoidal Salmonella spp. 0 1
Numbers are n (%).
Table 4 Logistic regression model for predictors of
outcome in HIV infected children (n = 115)
Adjusted odds ratio 95% CI p
Age (months) 1.00 0.97 – 1.04 0.9
Gender 0.61 0.23 – 1.62 0.3
Weight for age (%) 0.97 0.78 – 1.20 0.8
Cotrimoxazole prophylaxis 1.51 0.47 – 4.83 0.5
CD4 < 15% 3.59 1.43 – 9.01 0.006
PCP 1.12 0.36 – 3.52 0.8
CMV pneumonia 1.92 0.74 – 4.92 0.2
PCP pneumocystis pneumonia; CMV cytomegalovirus.
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fection, PCP and cotrimoxazole prophylaxis showed that
only HIV infection was predictive of mortality (OR 3.7,
95% CI 1.5 – 9.0; p = 0.004). In a separate model of 115
HIV infected children with complete data, only CD4
count <15% was significantly associated with mortality
(OR 3.6, 95% CI 1.4 – 9.0; p = 0.006) (Table 4). None of
the five HIV exposed uninfected infants with PCP died.
Discussion
PCP was diagnosed in more than half of children hospi-
talised with hypoxic pneumonia using molecular tech-
niques, more than double that diagnosed by IF or
Grocott staining on the same respiratory samples [2].
The incidence of PCP reported in prior studies based on
IF staining of respiratory secretions may therefore be a
large underestimate [1,2,6-10,29-32]. The study indicates
that PCP in HIV-infected infants is even more of a con-
cern than was previously recognised, and emphasises the
need to strengthen paediatric HIV programs including
early use of cotrimoxazole prophylaxis and HAART ac-
cording to current global guidelines [29,33].Table 3 Logistic regression model of predictive factors
for PCP
Variable Adjusted odds ratio 95% CI p
Cotrimoxazole prophylaxis 0.2 0.07 – 0.5 0.002
HIV infection 8.2 3.8 – 17.8 < 0.0001
CMV blood PCR positivity 2.4 1.2 – 5.0 0.02
Fever 0.3 0.4 – 0.6 0.001
Respiratory rate >60
breaths per minute
3.5 1.7 – 7.0 0.0005
CMV-cytomegalovirus; CI- confidence interval. Lactate dehydrogenase and
oxygen saturation were not included due to missing data.Cotrimoxazole prophylaxis and HAART had been insti-
tuted in only a minority of eligible children despite the
free availability of HAART and PMTCT programs in
this area of South Africa. Reassuringly, cotrimoxazole pro-
phylaxis was found to be highly effective for preventing
PCP, supporting the widespread use of this cost-effective
intervention [29,34,35]. Although this study was not de-
signed to investigate implementation of national policies
for paediatric HIV or adherence to HAART or cotrimo-
xazole, the results indicate that the HIV program is still
not functioning appropriately, with potentially devastating
consequences. Further research to investigate the under-
lying reasons for failure of the PMTCT and HAART pro-
grams in this setting is needed.
The in- hospital case fatality rate for children with
PCP of 32% is within the range reported in other African
studies [1,9-11], and is also similar to that reported eight
years previously from the same study site [9].
A minority of HIV uninfected children also developed
PCP. Consistent with prior reports, a number of risk fac-
tors were identified [1,9,11,36] including malnutrition
and HIV exposure [4,12,14,15]. HIV exposed infants
may be at increased risk of PCP due to impaired im-
munity, exposure to P. jirovecii from an HIV infected
mother or adult, or poor protection from maternal anti-
bodies [4,12,15,37,38]. All HIV exposed but uninfected
infants with proven PCP survived, consistent with previ-
ous reports of better outcome in HIV uninfected com-
pared to HIV infected infants [16]. With strengthening
of PMTCT programs, HIV exposed but uninfected in-
fants are an increasingly important group who may be at
risk for PCP. The use of cotrimoxazole prophylaxis in
this group deserves further consideration given the in-
creasing number of case reports of PCP in HIV-exposed
uninfected infants and this growing population [4,39].
Clinical and laboratory measures associated with PCP
were similar to previous reports [2,32]. Although ele-
vated LDH may be a non-specific marker of lung injury
[40], these results suggest that there should be a high
index of suspicion of PCP in those children with raised
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ticularly when there are other known risk factors for
PCP.
As expected, co-infection with P. jirovecii and other path-
ogens, particularly viruses, was common [2-4,6,41,42]. Simi-
lar to previous studies, CMV coinfection occurred most
frequently, in a third of children with PCP [4,6,7,43,44].
This may also reflect severe immunosuppression as CMV
pneumonia has been associated with moderate or severe
immunosuppression in HIV-infected infants [4-6,43-46].
Limitations of this study include lack of a control group.
Several adult studies have reported carriage of P. jirovecii
as detected by a positive PCR on respiratory specimens
[22,47,48], however, positive PCR results in our study are
unlikely to represent colonisation given the presentation
of severe pneumonia, the young age of infants and the
protective effect of cotrimoxazole prophylaxis [23]. We
were unable to use response to treatment as a means of
confirming PCR diagnosis as all children were treated for
presumptive PCP based on clinical signs. The lack of a
gold standard for PCP diagnosis makes testing of any new
diagnostic modality challenging, especially as the organism
cannot be easily cultured. This was a single- centre study
of a selected population admitted to a tertiary hospital;
therefore results may not be generalisable to children from
different geographical areas and with different clinical dis-
ease spectra. Further studies of PCR based diagnosis in
children with non-HIV immunosuppression are needed.
Conclusions
PCP remains a common cause of severe hypoxic pneumo-
nia and is associated with high mortality in HIV-infected
African infants. New molecular diagnost ic methods indi-
cate that the burden of PCP in this populat ion has been
under -est imated in the past.
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